Compare Citius Pharmaceuticals Inc (CTXR) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Marathon Petroleum Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Marathon Petroleum Corp trades at $459.1 (market cap $124.20B). The key difference: Marathon Petroleum Corp is far larger — about 9006.5× Citius Pharmaceuticals Inc's market cap, and Marathon Petroleum Corp pays a 0.9% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Marathon Petroleum Corp for 54 Days on average.
| CTXR | MPC | |
|---|---|---|
Market Cap | $13.79M | $124.20B |
Volume | 156,684 | 1,923,373 |
Sector | Health | Energy |
52-Week High | $1.82 | $463.34 |
52-Week Low | $0.48 | $162.63 |
Typical Hold Time | 16 Days | 54 Days |
Enterprise Value | $3.96M | $150.72B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Marathon Petroleum (MPC) trades at $442.26, up 2.29% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with a P/E of 15.33, ROE of 47.9%, and consistent earnings beats in recent quarters. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export restrictions pose headwinds. Technical indicators show the stock trading near pivot point resistance at $442 with RSI suggesting potential overbought conditions.
MPC presents a compelling value opportunity with attractive valuation metrics and strong profitability, though investors face risks from potential regulatory changes and volatile energy markets. Analyst consensus remains strongly bullish with 76% buy ratings and a $420.30 price target, suggesting modest downside from current levels. The company's solid cash flow generation and dividend payments provide shareholder returns support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
